Trial Profile
A Phase II, Multicentric, Open Label, Non-randomized, Interventional Study of Pembrolizumab in Combination With Electrochemotherapy in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jul 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Bleomycin
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms ECT_PEMBRO
- 27 Jun 2023 Planned End Date changed from 1 Jan 2023 to 1 Dec 2023.
- 27 Jun 2023 Planned primary completion date changed from 1 Jan 2023 to 1 Dec 2023.
- 12 May 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2023.